Resources

Selinexor (KPT-330), a novel selective inhibitor of nuclear export (SINE), shows single agent efficacy against alveolar soft part sarcoma (ASPS) in vivo

• PDF (928.94 KB)

Genomic and molecular characterization of esophageal squamous cell carcinoma

• External Link

Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study

• External Link

Safety and Anti-tumor Activity of Selinexor (KPT-330), a First-in-Class, Oral XPO1 Selective Inhibitor of Nuclear Export (SINE) – A Phase I Study Expanded with Colon Cancer Cohort

• PDF (1.49 MB)

XPO1 (CRM1) inhibition represses STAT3 activation to drive a surviving-dependent oncogenic switch in triple negative breast cancer.

• External Link

Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

• PDF (2.17 MB)

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)

• PDF (1.24 MB)

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

• PDF (3.12 MB)

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias

• External Link

Genome wide studies in Multiple Myeloma identify XPO1/CRM-1 as a critical target validated using the selective nuclear export inhibitor KPT-276.

• External Link